Disclosed herein are methods for selecting an antibody fragment specific to an influenza virus. According to certain embodiments of the present disclosure, the influenza virus may be influenza virus type A (IAV) or influenza virus type B (IBV). Also disclosed herein are the selected antibodies, recombinant antibody produced from the selected antibodies, and the uses thereof in the diagnosis of influenza virus infection.

A method is disclosed for measuring a sample, in which the sample to be analysed is measured using a measuring device in connection with a development of a measurement of the sample. On the basis of the measurement, information concerning an usability of the measurement and/or an analysis result is formed in connection with a development of a measurement of the sample using a calibration comprising a set of criteria and the corresponding information is reported.

A method for detecting a trace protein in a sample system, comprising: providing a primary antibody-modified immunomagnetic bead and a secondary antibody-modified nanoparticle for a to-be-detected protein; mixing and incubating the primary antibody-modified immunomagnetic bead and the secondary antibody-modified nanoparticle with a sample system containing the to-be-detected protein, so as to form a complex having a double-antibody sandwich structure; and allowing the complex to pass through a micro-nano pore device in the form of a single particle and trigger an electrical pulse signal, analyzing the electrical pulse signal to obtain a charge state or a volume/mass state of the complex, and calculating, according to the charge state or the volume/mass state, the amount of the to-be-detected protein in the sample system.

Disclosed are methods and systems for detecting SARS-CoV-2 analytes in dried samples, as for example, dried blood spots. For example, disclosed is a method for measuring an analyte of interest in a dried sample comprising: (a) obtaining a dried sample from a subject; (b) extracting the analyte of interest from the dried sample; and (c) detecting the analyte of interest extracted from the dried sample. In certain embodiments, the analyte of interest is an analyte specific to SARS-CoV-2. Also, the method may include a step of determining a cutoff index (COI) indicative of whether the subject has a detectable amount of the analyte of interest and so is defined as positive, or does not contain a detected amount of the analyte of interest and so is defined as negative, or is defined as indeterminate.

An exosome to be analyzed having a first bead and a second bead bound thereto is collected from a buffer fluid containing the exosome to be analyzed having the first bead and the second bead bound thereto. A first antibody that specifically binds to a first antigen associated with a first disease is fixed to a surface of the first bead. A second antibody that specifically binds to a second antigen associated with a second disease is fixed to a surface of the second bead. The first bead is separated from the exosome, and the exosome having the second bead bound thereto is collected. The exosome having the second bead bound thereto is dissolved, and the second bead and an inclusion of the exosome are collected. The inclusion of the exosome is analyzed, and the number of second beads is counted.

The purpose of the present invention is to provide a method for detecting, in a selective and simple manner, an oxidized form of HD5 which is human α-defensin, that is, HD5 having intramolecular disulfide bonds that function beneficially in the human body.

[Solution] The present invention relates to: two kinds of novel monoclonal antibodies that contain amino acid sequences of SEQ ID NO: 1-6 or 7-12 as a CDR and that specifically bind to human α-defensin HD5 having intramolecular disulfide bonds; an immunological detection method using the antibodies; and a kit containing the antibodies.

Two methods for quantifying fibrin/fibrinogen degradation products (“FDP”) in a blood sample. The first method features obtaining a blood sample from a non-human animal, centrifuging the blood sample to obtain a first supernatant and collecting the first supernatant, centrifuging the first supernatant to obtain a second supernatant and collecting the second supernatant, diluting the second supernatant, contacting the diluted second supernatant with a reagent that contains antibodies specifically binding to FDP, and detecting an amount of antibodies specifically bound to FDP, thereby quantifying FDP in the blood sample. The second method requires subjecting the diluted second supernatant to a quantitative immunoassay that specifically detects FDP to quantify the amount of FDP in the non-human blood sample.

Disclosed is a novel method showing a higher detection sensitivity for hepatitis B virus genotype D than those of known methods. A method of immunoassay of hepatitis B virus core-related antigen uses, as an antibody to be used for the immunoassay, a monoclonal antibody that specifically binds to at least one kind of core-related antigen of hepatitis B virus genotype D, or an antigen-binding fragment thereof, wherein an epitope of the monoclonal antibody or the antigen-binding fragment thereof is a region included in the amino acid sequence from position 31 to 48 of SEQ ID NO:3.

The invention concerns methods for early detection, monitoring and prognosis of a flavivirus-induced infection, comprising the detection of a complex formed by the flavivirus non-structural glycoprotein NS1 and plasma lipoprotein particles in a biological anti-NS1 Mab sample during the clinical phase of the infection.

Antibodies that detect M. hyopneumoniae, methods of making those antibodies, and methods of using those antibodies including, for example, in a diagnostic immunoassay, are described. Such a diagnostic assay may be used in pen-side testing for detection of M. hyopneumoniae.